The $4 Billion No-Sale Reactor: NuScale’s 83% Collapse Looks Rational, Not Oversold

(SeaPRwire) –   By: Cedric Cole

NuScale Power is not a business yet. It is a $4 billion wager on small modular reactors with no first sale. The stock trades around $9.70. That is an 83% drop from the 52-week high of $57.42. I have seen this movie before. A hard-science story gets wrapped in a public listing, cash burn accelerates, and the market slowly reprices the gap between ambition and order book. The troubling part is not the share price. It is that the company just posted $0.07 million in quarterly revenue. That is a 99.1% decline from the same period a year ago. Analysts expected $8.80 million. NuScale missed by nearly the entire amount. Yet the market cap still sits near $4 billion. The company is in mid-cap territory with almost no revenue. That disconnect is the real story.

The revenue line is almost ornamental. NuScale has no firm first sale for its small modular reactor technology. The commercial future remains unproven. The company matched analyst earnings expectations with a loss of $0.13 per share. The full-year consensus forecast is a loss of $0.64 per share. Those numbers tell you the current cost of keeping the lights on. They do not tell you when a paying customer arrives. Longtime shareholder Fluor exited its position. That is a serious signal. Fluor understands complex energy construction. When a backer with that kind of industrial knowledge walks away, retail investors should ask what it knows. Insider selling adds more noise. CFO Robert Hamady sold nearly 30,000 shares in late August at $9.39. COO Carl Fisher sold over 18,000 shares in early August. Both sales were tied to tax obligations from vesting equity. I do not read those as panic moves. But combined insider sales of 68,651 shares over three months do not scream conviction either.

Then comes the capital structure problem. NuScale announced a $750 million share sale. That is dilution risk for existing holders. The company also made a $506 million milestone payment to ENTRA1 Energy. The payment is related to a potential SMR deployment with the Tennessee Valley Authority. “Potential” is the operative word. A $506 million cash outflow tied to a project that has not produced a firm first sale is not a small thing. It is a cash burn accelerant. Put the arithmetic in plain terms. The company generated less than one-tenth of one million dollars in quarterly revenue. It is forecast to lose $0.64 per share this year. It just agreed to a share sale that could raise $750 million. That is more than 18% of the current market cap. If the stock is weak, the share sale will be expensive. If the share sale is expensive, existing shareholders absorb the pain. This is not complex financial engineering. It is basic dilution math.

The institutional tape is mixed. Vanguard increased its stake by 40.5%. Van ECK Associates nearly doubled its position. Morgan Stanley added to its holdings. Total institutional and hedge fund ownership stands at 78.37%. Some bulls will point to those buys as conviction. I see it differently. Index-linked and thematic funds often buy a falling small-cap energy name to maintain exposure. The buys do not confirm that a first commercial sale is near. The analyst community is not exactly pounding the table. The consensus rating is a Hold. The average price target is $13.50. That is above the current price, but price targets on pre-revenue names are often stale. Bank of America rates it Neutral with a $12 target. Truist says Hold with a $10 target. Goldman Sachs is at $9. B. Riley and Canaccord still have Buy ratings. But both cut their targets recently. B. Riley went from $19 to $15. Canaccord went from $25 to $15. Of 17 analysts covering the stock, one has a Strong Buy, four have a Buy, nine have a Hold, and three have a Sell. That is not a wall of confidence. That is a market waiting for a reason to believe.

The volatility math confirms the speculative profile. NuScale has a beta of 2.30. The 50-day moving average is $9.12. The 200-day sits at $10.80. The 52-week low is $7.21. The stock is closer to the low than the high. If you are an investor, stop asking whether nuclear power is a good long-term theme. That question does not matter here. The question is whether this company can survive long enough to convert a theme into a contract. Right now the evidence says no. No firm first sale. Revenue down 99.1%. Fluor gone. Insider sales. A $750 million dilutive shelf. A half-billion dollar milestone payment for a potential project. The market has not lost its mind by marking this down 83%. It has started to price the gap between a science project and a going concern. The next liquidity correction will be harder. If the share sale prints below the current price, the $13.50 average target becomes fiction. If the company cannot show a signed customer, that $4 billion market cap will keep bleeding toward the value of its cash and half-finished partnerships. I would not short it blindly. The beta is 2.30, and it can rip higher on a single headline. But I would not call it oversold either. The smart trade is not to catch the falling reactor. It is to wait for a sales contract that actually exists.

Author bio: Cedric Cole, a forensic accountant and advisor to private equity restructuring partners, focused on cash-burn models and distressed pre-revenue industrial bets.